Exopharm Ltd
ASX:EX1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Exopharm Ltd
Revenue
Exopharm Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Exopharm Ltd
ASX:EX1
|
Revenue
AU$3.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
139%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Revenue
$65.4m
|
CAGR 3-Years
93%
|
CAGR 5-Years
32%
|
CAGR 10-Years
13%
|
|
|
CSL Ltd
ASX:CSL
|
Revenue
$15.4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Revenue
AU$3.4m
|
CAGR 3-Years
153%
|
CAGR 5-Years
189%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Revenue
AU$803.8m
|
CAGR 3-Years
98%
|
CAGR 5-Years
174%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Revenue
AU$24.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
55%
|
CAGR 10-Years
86%
|
|
Exopharm Ltd
Glance View
Exopharm Ltd. engages in the development and commercialization of exosomes as therapeutic agents. The company is headquartered in Melbourne, Victoria. The company went IPO on 2018-12-18. The firm is focused on developing and commercializing exosomes as therapeutic agents. The firm has three technologies that allows customization of exosomes, in which the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types. Its LEAP manufacturing technology provides access to exosomes for research and clinical uses. The firm is developing Engineered EVs (EEVs), are an emerging form of precision medicine with application in areas, such as neurology, cardiology and oncology. Its EEV projects under development are Fortrexo, Cognevo and PlexoDOX.
See Also
What is Exopharm Ltd's Revenue?
Revenue
3.4m
AUD
Based on the financial report for Jun 30, 2023, Exopharm Ltd's Revenue amounts to 3.4m AUD.
What is Exopharm Ltd's Revenue growth rate?
Revenue CAGR 5Y
139%
Over the last year, the Revenue growth was -19%. The average annual Revenue growth rates for Exopharm Ltd have been 8% over the past three years , 139% over the past five years .
